42 Results
Addressing Liver and Cardiovascular Disease among People with HIV and HIV Prevention During Pregnancy: Dr. Dieffenbach’s Second Update from CROI 2024 (VIDEO)
On Tuesday at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI), HIV.gov spoke with Carl Dieffenbach, Ph.D., director of NIAID’s Division of AIDS, about research on common health complications of HIV and the safety of an HIV prevention tool during pregnancy. He spoke with Miss Molly Moon, M.S.W., Deputy Director of the NIH-supported Office of HIV/AIDS Network Coordination. Watch their conversation.
Doxy-PEP, HIV Vaccines and Community-Engaged Research: Discussions with Carl Dieffenbach and LaRon Nelson at CROI 2024 (VIDEO)
During the first full day of presentations at the 2024 Conference on Retroviruses and Opportunistic Infections, HIV.gov spoke with Carl Dieffenbach, Ph.D., director of NIAID’s Division of AIDS, and LaRon Nelson, Ph.D., R.N., F.N.P., F.N.A.P., F.N.Y.A.M., F.A.A., professor and associate dean at the Yale School of Nursing. They discussed Doxy-PEP for STI prevention, HIV vaccines, community engagement in research, and more. Watch their discussions.
NIAID’s Dr. Jeanne Marrazzo Previews CROI 2024 (VIDEO)
HIV.gov opened their coverage of the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) today with a conversation with NIAID Director Jeanne Marrazzo, M.D., M.P.H. She spoke with Miguel Gomez, director of HIV.gov about what she’s looking forward to hearing about at the conference, how the studies presented at research conferences ultimately get translated into clinical practice or HIV prevention or treatment services, and the important roles of early-career investigators. Watch their conversation with Dr. Marrazzo.
Toward a Deeper Understanding of Effective Oral HIV Pre-Exposure Prophylaxis Use in Cisgender Women
Pivotal studies supported by NIAID demonstrated that oral pre-exposure prophylaxis (PrEP) reduces an individual’s likelihood of acquiring HIV through sex by up to 99% when taken as prescribed. Research has revealed important differences in individual and population-group preferences in oral PrEP use, particularly that cisgender women participating in studies often did not take oral PrEP as prescribed—and the intervention’s effectiveness declined when doses were taken less frequently. Jeanne Marrazzo, M.D., M.P.H. and colleagues conducted a pooled analysis of data from post-marketing demonstration projects to to characterize the relationship between oral PrEP use and its efficacy among cisgender women.
New Guidelines for Use of Statins by People with HIV to Prevent Cardiovascular Events
The Department of Health and Human Services Guidelines Panel for the Use of Antiretroviral Agents in Adults and Adolescents with HIV (the Panel) has developed recommendations for the use of statin therapy in people with HIV, in collaboration with representatives from the American College of Cardiology, the American Heart Association, and the HIV Medicine Association.
Working Together to End HIV in Black Communities
Health inequities and disparities disproportionately affect Black people and other historically marginalized groups at above average rates. NIAID highlights ongoing efforts to reduce the burden of HIV among Black Americans while increasing the representation of Black communities and researchers in HIV science.
The STOMP Trial Evaluates an Antiviral for Mpox
NIAID launched the STOMP trial to determine whether the antiviral drug tecovirimat can safely and effectively treat mpox. In a video, Dr. Cyrus Javan of NIAID's Division of AIDS explains the importance of the STOMP trial.
Among People Living with HIV, Study Finds Higher Burden of Aging-Related Comorbidities in Women Than Men
The growing uptake of antiretroviral therapy (ART) has resulted in an increase in the lifespan of persons with HIV (PWH); however, aging-related non-AIDS comorbidities (NACM) are now on the rise and present a new health challenge.
Final IAS 2023 Conversations—HIV & STI Prevention, Stigma, and U=U
As the International AIDS Society’s 12th Conference on HIV Science (IAS 2023) conference drew to a close on Wednesday, HIV.gov continued our conversations about the latest research being presented, with updates on post-exposure prophylaxis for STIs (Doxy-PEP), implementation of HIV PrEP, and the effectiveness of U=U.
IAS 2023—HIV Vaccines, bNAbs, and an Update from NIH’s Office of AIDS Research
This blog is cross-posted from HIV.gov.
On Tuesday at the International AIDS Society’s 12th Conference on HIV Science (IAS 2023), HIV.gov continued our conversations about research highlights, including a focus on the latest about HIV vaccines. We also heard an update from the NIH Office of AIDS Research.
NIH’s Carl Dieffenbach, Ph.D., Director of the Division of AIDS at the National Institute...
Conversations at the Opening of IAS 2023
The International AIDS Society’s 12th Conference on HIV Science (IAS 2023) opened Sunday, with thousands of scientists, policy leaders, and advocates gathered to present and discuss the latest advances in HIV research. HIV.gov’s coverage of the conference began with two video conversations looking ahead to the exciting research that will be presented.
IAS Conference Highlights—Heart Disease Prevention for People with HIV, Long-acting HIV Prevention and Treatment
During the first full day of sessions at the International AIDS Society’s 12th Conference on HIV Science (IAS 2023), HIV.gov shared conversations on important study findings about reducing cardiovascular disease among people with HIV and the latest developments with long-acting prevention and treatment options that could one day become safe and effective alternatives to daily oral pills.
Register Now! Live with Leadership—A Conversation Commemorating National HIV Vaccine Awareness Day
Register now to take part in an important conversation about National HIV Vaccine Awareness Day—an annual observation to recognize the many community members, health professionals, and scientists working together to develop a vaccine to prevent HIV. The HIV.gov-hosted Live with Leadership conversation will take place on Thursday, May 18, from 2:30–3:00pm ET.
This engaging...
Multisite Study Identifies Factors Associated with HIV Incidence Among Transgender Women
Despite the high HIV burden among transgender women, access to health care among this demographic is low due to structural barriers that limit access to HIV prevention, testing, care, and other health services. Therefore, transgender women have been identified as a priority population in the Ending the HIV Epidemic in the U.S. (EHE) plan and National HIV/AIDS Strategy.
CROI 2023—Dr. Dieffenbach Shares Research Highlights on Long-Acting HIV Prevention and Treatment, COVID, and a Cure Update
Dr. Dieffenbach, Director of the Division of AIDS, shared updates about some research on long-acting HIV prevention and treatment and COVID treatment and prevention. He also discussed news of another reported case of HIV cure.
HIV Vaccine Research Update with Dr. Dieffenbach from CROI 2023
The ongoing search for an HIV vaccine was among the topics discussed during the 2023 Conference on Retroviruses and Opportunistic Infections (CROI). HIV.gov spoke with Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Disease, about some key takeaways from those presentations. Watch our conversation with Dr. Dieffenbach below:
Mosaico...
Doxy-PEP for STIs and More—Dr. Dieffenbach’s Highlights from Day 1 of CROI 2023
During the first full day of research presentations at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI), HIV.gov spoke with Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID), about some initial highlights, including the opening session that featured a lecture by Dr. Anthony Fauci and several studies...